Xuejiao Yin, Yi Liu, Jianai Sun, Hongyan Tong, Haitao Meng, Liangshun You
{"title":"Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting.","authors":"Xuejiao Yin, Yi Liu, Jianai Sun, Hongyan Tong, Haitao Meng, Liangshun You","doi":"10.1177/20406223231213251","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules on the surface of malignant plasma cells and CD3 on the surface of T cells.</p><p><strong>Objectives: </strong>Addressing the issue of improving the prognosis of triple-class refractory MM patients has become a significant clinical challenge.</p><p><strong>Design: </strong>This is a brief report.</p><p><strong>Methods: </strong>This article summarizes the latest updates of BsAbs treatment of MM from the 2022 ASH annual meeting.</p><p><strong>Results: </strong>BsAbs that target B-cell maturation antigen and G protein-coupled receptor family C group 5 memberD have demonstrated remarkable clinical activity and favorable safety profiles. Many potential targets for myeloma cells are currently undergoing phase I/II clinical trials, and these off-the-shelf bispecific molecules are likely to become a critical part of the MM treatment landscape.</p><p><strong>Conclusion: </strong>This article provides an overview of the latest advances in BsAbs immunotherapy for refractory and relapsed MM and highlights significant findings from the 2022 ASH annual meeting.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657518/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223231213251","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules on the surface of malignant plasma cells and CD3 on the surface of T cells.
Objectives: Addressing the issue of improving the prognosis of triple-class refractory MM patients has become a significant clinical challenge.
Design: This is a brief report.
Methods: This article summarizes the latest updates of BsAbs treatment of MM from the 2022 ASH annual meeting.
Results: BsAbs that target B-cell maturation antigen and G protein-coupled receptor family C group 5 memberD have demonstrated remarkable clinical activity and favorable safety profiles. Many potential targets for myeloma cells are currently undergoing phase I/II clinical trials, and these off-the-shelf bispecific molecules are likely to become a critical part of the MM treatment landscape.
Conclusion: This article provides an overview of the latest advances in BsAbs immunotherapy for refractory and relapsed MM and highlights significant findings from the 2022 ASH annual meeting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
